We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Minister Seán Sherlock is shown how the blood test works.
early spot

Early screening test for pre-eclampsia being developed by Irish startup

The bioscience company has received three-quarters of a million euro to develop what it calls “breakthrough blood test”.

AN IRISH BIOSCIENCE company has secured €750,000 to develop a test which could detect pre-eclampsia risk in pregnant women at an early stage of their pregnancy.

Pre-eclampsia can be a fatal condition and doesn’t generally make itself known until the second half of the term of pregnancy. At that time, the only treatment option should it escalate (the high blood pressure symptom can be incredibly dangerous for mother and baby) can be early delivery of the baby.

Irish start-up Metabolomic Diagnostic is developing a blood test called ‘PrePsia’ which it is hoped will detect women at high risk of developing pre-eclampsia, allowing for early treatment before the condition deteriorates.

Junior minister for research and innovation, Seán Sherlock, said that the investment from Enterprise Ireland, AIB Seed Capital Fund and SOSventures Ireland Fund is vital. He said:

This is an important investment, given the potential significance of this metabolomic diagnostic test, the results of which include saving lives.

There are currently 5,000 pregnant women from all over Europe involved in giving blood specimens to test Metabolomic Diagnostics technology.

The company is based in Little Island in Cork.

For those seeking further information, clarification and support on pre-eclampsia, visit, the website of the Pre-eclampsia Foundation, a registered charity and patient advocacy group.

Breast cancer patients who stop oral hormone therapy increase risk of recurrence>
Test made in Longford can help docs spot if you’re having a heart attack>

Your Voice
Readers Comments
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.